论文部分内容阅读
[目的]对比分析雷贝拉唑与奥美拉唑治疗反流性食管炎的临床效果。[方法]选取2010~2013年于我院就诊的反流性食管炎患者120例,随机均分为2组,治疗组在一般治疗的基础上,给予雷贝拉唑肠溶胶囊,20mg/d,每日早晨空腹服用;对照组给予奥美拉唑肠溶片20mg/d,每日早晨空腹服用,其他治疗方法同治疗组,疗程均为8周。[结果]治疗组痊愈率为93.33%,明显高于对照组65.00%,2组差异有统计学意义。内镜下显示治疗组痊愈率为91.67%,明显高于对照组53.33%;治疗组不良反应发生率为1.67%,显著低于对照组26.67%;治疗组的复发率为5.00%,显著低于对照组(30.00%),2组差异均有统计学意义。[结论]相较于奥美拉唑而言,雷贝拉唑有起效快、疗效好、不良反应及复发率低等优点,值得临床推广应用。
[Objective] To compare and analyze the clinical effects of rabeprazole and omeprazole in the treatment of reflux esophagitis. [Methods] 120 patients with reflux esophagitis who were treated in our hospital from 2010 to 2013 were randomly divided into 2 groups. On the basis of general treatment, the treatment group was given rabeprazole enteric-coated capsules, 20mg / d , Take an empty stomach daily morning; the control group was given omeprazole enteric-coated tablets 20mg / d, taken on an empty stomach daily morning, other treatment methods with the treatment group, the course of treatment were 8 weeks. [Results] The cure rate in the treatment group was 93.33%, which was significantly higher than that in the control group (65.00%). The difference between the two groups was statistically significant. The cure rate of the treatment group was 91.67%, which was significantly higher than that of the control group (53.33%). The incidence of adverse reactions in the treatment group was 1.67%, which was significantly lower than that in the control group (26.67%). The recurrence rate was 5.00% in the treatment group The control group (30.00%), two groups of differences were statistically significant. [Conclusion] Compared with omeprazole, rabeprazole has the advantages of rapid onset, good curative effect, low adverse reactions and recurrence rate, which is worthy of clinical application.